{"filings":[{"id":2285716,"accession_number":"0001437749-26-028120","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2026-08-17T13:57:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longevity Health settles Puritan litigation; issues $2.35M 10% convertible notes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Puritan Partners resolves litigation pending since Nov 2023; parties to file dismissal without prejudice within 3 business days.","Existing note and warrant exchanged for new 10% senior secured convertible notes, aggregate principal $2,350,000, maturing Feb 2028.","CEO Ram Ajjarapu says litigation had hindered capital raising and strategic opportunities; resolution removes overhang and enables execution of commercial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-17","daily_digest_url":"/daily/2026-08-17","daily_digest_rank":6},{"id":2271718,"accession_number":"0001437749-26-028011","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2026-08-14T20:11:37+00:00","items":["1.01","2.03","1.02","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Longevity Health settles Puritan litigation with $2.35M convertible notes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Puritan Partners resolves NY lawsuit; Existing Note ($1.25M) and warrant (1,885,796 shares) exchanged for new 10% convertible notes totaling $2.35M.","New notes mature Feb 5, 2028, convertible at $0.50/share, with alternative conversion at 80% of 5-day VWAP if below; secured by first lien on all assets.","Company must offer to prepay 25% of gross proceeds from future financings; confession of judgment for principal plus default interest.","Scott Frisch resigned from board effective Aug 11, 2026, no disagreement cited.","Litigation dismissed without prejudice within 3 business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861926,"accession_number":"0001193125-26-257520","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2026-06-04T20:30:16+00:00","items":["5.02"],"status":"ready","headline":"Director Kathryn Gregory resigns from Longevity Health Holdings board effective June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathryn Gregory resigned from the Board of Directors effective June 1, 2026.","Resignation was not due to any disagreement with the Company's operations, policies or practices.","No successor or replacement has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109764,"accession_number":"0001193125-26-109472","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Longevity Health appoints new CEO, closes $200K investment from new chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ram Ajjarapu appointed Chairman and CEO effective March 16, 2026; invested $200K via private placement of 689,656 shares at $0.29.","Rajiv Shukla resigned as CEO and Chairman; separation includes 12 months of $30K/month severance plus $480K bonus upon $1M capital raise.","Company intends to use proceeds for working capital and pursue acquisition-focused growth strategy.","Shares issued in unregistered private placement; resale registration statement to be filed within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126296,"accession_number":"0001193125-25-317638","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Longevity Health terminates merger agreement with True Health after Nov 30 deadline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Company provided termination notice on Dec 8, 2025; merger not consummated by Nov 30, 2025.","No termination fee payable by either party under Merger Agreement.","Deal originally signed July 14, 2025; amended Nov 3, 2025; failed to close by deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126295,"accession_number":"0001193125-25-272538","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Longevity Health amends merger terms with True Health; sets $3 cap on exchange price","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger Shares capped at $59M divided by lesser of 15-day VWAP and $3.00, reducing potential dilution if stock exceeds $3.","Earnout Shares capped at $20M divided by lesser of 15-day VWAP and $3.00, with same price floor.","Amendment executed Nov 3, 2025, altering original July 14, 2025 Agreement; all other terms unchanged.","Merger consideration now linked to Parent Market Price: volume-weighted average closing price over 15 days pre-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143047,"accession_number":"0000950170-25-114421","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longevity Health delisted from Nasdaq, now trades on OTC; merger with True Health planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received delisting notice from Nasdaq on Sept 10, 2025 for failure to cure Listing Rule 5550(b)(2) deficiency.","Securities delisted at open Sept 12, 2025; common stock and warrants began trading on OTC Markets.","Company states operations unaffected; will continue periodic SEC filings.","Intends to pursue previously disclosed merger with True Health Inc. and relist on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143046,"accession_number":"0000950170-25-095608","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","5.01","8.01","9.01"],"status":"ready","headline":"Longevity Health to merge with THPlasma in $59M all-stock deal; Biolabs terminated","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger values THPlasma at $59M plus $20M earnout; Longevity shares at $3.00 (12% premium to July 11 close).","THPlasma has 5 plasma centers; FY2025E revenue $10M, EBITDA $2M; FY2026E revenue $32M, EBITDA $7M.","Post-closing (Q4 2025), Rajiv Shukla becomes Executive Chairman; George Chi becomes Co-Chairman & CEO.","Prior merger with 20/20 Biolabs automatically terminated July 8, 2025; no termination fees.","No cash condition precedent; approved by both boards, subject to stockholder and Nasdaq approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161157,"accession_number":"0000950170-25-090015","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Longevity Health extends merger deadline with 20/20 Biolabs to July 8, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Due Diligence Contingency Deadline moved to July 8, 2025; merger agreement will auto-terminate on that date unless extended in writing.","Amendment signed June 24, 2025; original Agreement and Plan of Merger dated April 11, 2025.","No other provisions of the merger agreement were modified beyond the deadline extension.","Parties: Longevity Health Holdings, Merger Sub, 20/20 Biolabs, and stockholder representative Jonathan Cohen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161156,"accession_number":"0000950170-25-077905","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longevity Health raises ~$1.96M via ATM sale of 479,621 shares at $4.08","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 479,621 shares of common stock at average $4.08/share, gross proceeds ~$1.96M before fees.","Cash runway extended into Q1 FY26 based on pro forma FY24 sales, excluding planned 20/20 merger.","CEO cites continued investor confidence as company advances merger with 20/20 Biolabs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161155,"accession_number":"0000950170-25-075865","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq panel grants conditional continued listing for Longevity Health pending merger with 20/20 Biolabs by Sept 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing condition: complete merger with 20/20 Biolabs and meet initial listing rules by Sept 2, 2025.","Company filed S-4 for merger on May 8, 2025, and effected 1-for-30 reverse stock split on May 12, 2025.","Panel based decision on review of financial statements and pro forma projections of combined company.","Chairman/CEO Rajiv Shukla stated focus on completing merger to satisfy Nasdaq requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161154,"accession_number":"0000950170-25-072931","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).","Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.","1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.","Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.","Company evaluating options for additional financing, anticipates primary investment in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161153,"accession_number":"0000950170-25-068578","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Longevity Health Holdings executes 1-for-30 reverse stock split effective May 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-30, effective 9:00 a.m. ET on May 12, 2025.","Shares reduced from ~30.1M to ~1M; no fractional shares issued (rounded up).","Common stock to trade split-adjusted on Nasdaq starting May 14, 2025 under ticker XAGE.","CUSIP changed to 142922129 for common stock; warrants CUSIP unchanged.","Proportional adjustments made to outstanding options, warrants, and equity plan shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161152,"accession_number":"0000950170-25-053506","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","5.01","8.01","9.01"],"status":"ready","headline":"Longevity Health signs merger with 20/20 Biolabs; combined co. valued ~$99M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock merger: 20/20 stockholders to own ~50.1% of combined co. (pre-concurrent financing).","Combined co. FY2025 revenue forecast to double to ~$7-8M from ~$3-4M; ~$1M synergies expected.","Post-closing: Jonathan Cohen (20/20 CEO) becomes CEO; Rajiv Shukla remains Chairman.","Concurrent financing to raise min. $4M gross proceeds; also at-market offering for up to $2M common stock.","Closing expected Q3 2025; subject to stockholder approvals, Nasdaq listing, and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161151,"accession_number":"0000950170-25-049943","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longevity Health receives Nasdaq delisting notice for bid-price deficiency; hearing April 15","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to regain $1.00 minimum bid price by March 31, 2025 compliance deadline.","Nasdaq Determination Letter (April 1) adds bid-price deficiency as additional delisting basis.","Deficiency will be considered at April 15 hearing alongside existing MVLS shortfall.","Company intends to seek extension from Nasdaq Hearings Panel; no assurance of success.","Tickers XAGE (common) and XAGEW (warrants) at risk of delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179317,"accession_number":"0000950170-25-047788","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2025-03-31T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Longevity Health acquires skincare business with $2M net loss and going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired skincare business from PMGC Holdings for undisclosed value; sale closed Jan 16, 2025.","Nine-month revenue $1.75M, gross profit $1.28M, net loss $2.01M.","Operating cash flow negative $2.24M; working capital only $249K.","Audited 2023 and unaudited 2024 financials filed; going concern warning issued by management.","Net investment by parent $402K; business funded by parent contributions of $2.25M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179320,"accession_number":"0000950170-25-045392","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve reverse stock split and warrant issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 2 (reverse split 1:15 to 1:30) passed: 18.5M for, 0.55M against, no broker non-votes.","Proposal 1 (warrant issuance >20% of outstanding) passed: 14.7M for, 178k against, 3.9M broker non-votes.","Proposal 3 (adjournment) not needed; 63% quorum achieved on March 24, 2025.","Reverse split ratio to be set by Board at discretion; no effective date announced.","Warrants relate to Dec 23, 2024 Securities Purchase Agreement; exercise triggers dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179319,"accession_number":"0000950170-25-035950","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Carmell rebrands to Longevity Health (XAGE); guides FY25 rev $3-4M; names Vice Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Longevity Health Holdings effective March 5; tickers to XAGE/XAGEW March 10.","Patrick Sturgeon appointed Vice Chairman; previously CFO and board director since July 2023.","Combined sales grew 34% in Jan-Feb 2025 vs 2024 post Elevai acquisition.","Elevai's post-acquisition burn rate reduced >50% via overhead cost synergies.","FY25 revenue guidance $3-4M; Q2 2025 product launches include hair growth serum, soapless facial cleanser, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179318,"accession_number":"0000950170-25-033793","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq delisting notice for failing MVLS minimum; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to regain $35M MVLS compliance by Feb 26, 2025 deadline; notice received March 4.","Must appeal by March 11, 2025 or trading suspended on March 13; Form 25-NSE to follow.","Company intends to appeal but cautions no guarantee of success for continued listing.","Redeemable warrants (CTCXW) also subject to delisting along with common stock (CTCX)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179316,"accession_number":"0000950170-25-008865","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Kendra Bracken-Ferguson departs; Executive Chairman Rajiv Shukla appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kendra Bracken-Ferguson and Carmell mutually agreed to end her CEO role effective January 20, 2025.","She will receive $150,000 in six equal monthly installments under a separation and release agreement.","Rajiv Shukla, current Executive Chairman, appointed CEO effective January 24, 2025; he previously served as CEO until July 2024.","Shukla will continue in his role as Executive Chairman.","No arrangement or understanding with any other person, and no family relationships with officers or directors disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179315,"accession_number":"0000950170-25-006024","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell closes acquisition of Elevai Skincare; issues ~1.15M shares, $2.5M revenue portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase consideration: ~1.1M shares of Carmell common at $0.8488/sh, plus 117,814 holdback shares for 12-month indemnification.","Earnout: 5% of annual net sales from existing products for 5 years; $500k milestone if hair/scalp products reach $500k revenue within 24 months.","Acquired assets include product portfolio with FY2024 revenue ~$2.5M, inventory ~$1.0M, and accounts receivable ~$0.03M.","Post-closing Carmell common shares outstanding ~30.1M; Chairman expects synergies, expanded portfolio, and improved cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179314,"accession_number":"0000950170-25-001359","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell to acquire Elevai Skincare assets for ~$1.1M stock, earnout, and assumption of liabilities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price includes ~$1.1M in Carmell common stock (with $100K escrow), ~$57K cash on inventory sale, 5% net sales earnout for 5 years, and $500K milestone.","Assets include product portfolio with trailing 12-month revenue of ~$2.5M, ~$1.0M inventory, commercial team, and accounts receivable.","Acquisition expected to close by January 17, 2025, subject to customary closing conditions.","Carmell to issue unregistered shares as closing stock consideration with registration rights within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195996,"accession_number":"0000950170-24-141623","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell raises $1.85M in private placement of stock and warrants at $0.23/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 8,065,210 shares and equal 5-year warrants at $0.23 each; gross proceeds $1.85M.","Warrants exercisable after stockholder approval; potential additional $1.85M if exercised.","Closing expected Jan 2, 2025; proceeds for commercial team build-out and general purposes.","Post-closing shares outstanding approx. 29M; priced at slight premium to Dec 23 close.","Brookline Capital Markets acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195995,"accession_number":"0000950170-24-129329","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Carmell furnishes investor presentation for meetings; specific content unavailable in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for investor meetings on or after Nov 20, 2024.","Exhibit text is cut off; only title and partial cautionary statement visible.","No financial results, product updates, or other concrete data extractable from excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195994,"accession_number":"0000950170-24-112392","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq deficiency notice for bid price below $1; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Carmell on Sept 30, 2024 that its common stock failed to maintain minimum $1 bid price for 31 consecutive business days.","Company has until March 31, 2025 to regain compliance; closing bid price must be $1 for at least 10 consecutive days.","If not cured, Nasdaq may grant an additional 180-day period if other listing standards are met.","No immediate impact on trading of common stock (CTCX) or warrants (CTCXW); company evaluating options.","There is no assurance that Carmell will be able to regain compliance with the Minimum Bid Price Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212262,"accession_number":"0000950170-24-102375","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq MVLS deficiency notice; must regain $35M minimum by Feb 26, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MVLS fell below $35M minimum from July 15 to Aug 29, 2024.","Nasdaq gave 180 days (until Feb 26, 2025) to regain compliance.","Compliance requires MVLS ≥ $35M for 10 consecutive business days.","Failure may lead to delisting; Company reviewing options.","Trading of CTCX and CTCXW continues for now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212261,"accession_number":"0000950170-24-087128","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Carmell appoints Kendra Bracken-Ferguson as CEO; Rajiv Shukla becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajiv Shukla resigned as CEO July 29, 2024; he remains Executive Chairman.","Kendra Bracken-Ferguson appointed CEO effective July 30, 2024; salary $300k, bonus target 50%, options $700k.","New CEO has 20+ years beauty/wellness experience; founded BrainTrust, co-founded Digital Brand Architects.","Carmell added to Russell Microcap Index, reduced cash burn 50%, raised $3M, began commercial sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212260,"accession_number":"0000950170-24-084333","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Carmell Corp shareholders elect Richard Upton director, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Richard Upton elected Class I director with 9,525,320 votes for, 24,465 withheld, 1,921,908 broker non-votes.","Adeptus Partners, LLC ratified as independent auditor for FY 2024 with 11,455,591 for, 12,663 against, 3,439 abstain.","Quorum of 11,471,693 shares (56% of outstanding) present at July 12, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231183,"accession_number":"0000950170-24-041908","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell raises $3.0M in private placement of 1.33M shares at $2.25-$2.88","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.0M before fees; 1,331,452 shares sold at $2.25 per share to investors and $2.88 to CEO.","CEO participation at $2.88/share equal to April 3 closing price on Nasdaq.","Proceeds for general corporate purposes; officers/directors subject to 90-day lock-up.","Registration rights agreement to be filed within 30 days of closing covering resale of shares.","Post-closing shares outstanding expected to be ~20.58 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231182,"accession_number":"0000950170-24-039431","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Carmell completes sale of Axolotl Biologix, expects $4M annual cash burn reduction","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed March 26; consideration: 3.845M common shares, 4,243 preferred shares, cancellation of $8M notes payable.","Annualized cash burn expected to drop $4M based on AxoBio's January 2024 financials.","Total debt reduction of $15.6M ($7.6M subsidiary debt + $8M notes payable).","Tangible equity increased $7M from eliminating AxoBio's negative tangible equity.","EPS dilution reduced 29% via cancellation of 8.09M fully diluted shares; 19.25M shares outstanding post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249568,"accession_number":"0000950170-24-036123","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Carmell sells Axolotl Biologix subsidiary for shares and $8M note cancellation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Returns 3,845,337 common shares and 4,243 preferred shares to original sellers; cancels $8 million note payable.","Exits tissue graft space; sharpens focus on skincare product launches beginning March 2024 through Summer 2024.","Expects $4 million annualized drop in cash burn net of revenue from AxoBio's January 2024 run rate.","Reduces total debt by $15.6 million ($7.6M sub debt + $8M note); adds $7M tangible equity; cuts EPS dilution 29%.","Post-closing: 19.25 million common shares outstanding; retained focus on aesthetics pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249567,"accession_number":"0000950170-24-004791","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carmell adds Dr. Bradley Calobrace to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Calobrace is an internationally recognized plastic surgeon with private practices in KY and IN.","He has clinical faculty appointments at University of Louisville and University of Kentucky.","He co-chairs the Aesthetic Training Program Committee and serves on Aesthetic Society Board.","Dr. Calobrace has co-authored 10-year FDA clinical trials and published a textbook on augmentation mastopexy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249566,"accession_number":"0000950170-24-004786","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carmell Corp adds Dr. Sean Kelishadi to Scientific Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kelishadi is a board-certified plastic surgeon with a private practice in Newport Beach, CA.","He is an ASAPS-approved Fellowship Director and has delivered 26 lectures at major conferences.","Published 37 peer-reviewed papers in journals like Aesthetic Surgery Journal, Plastic and Reconstructive Surgery.","His research covers wound reconstruction, healing, and immunobiology with NIH-funded research background.","Chairman & CEO Rajiv Shukla cites Kelishadi's involvement in studying latest scientific developments in aesthetics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249565,"accession_number":"0000950170-24-004783","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carmell adds Dr. Gregory A. Buford to Scientific Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gregory A. Buford, board-certified plastic surgeon and master injectables trainer, joins SAB.","Appointment announced January 10, 2024; Buford will advise on skin and hair health product development.","Buford is founder of Core Aesthetics Training Institute and Castle Connolly Top Doctor 2017-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249564,"accession_number":"0000950170-24-004762","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Carmell adds plastic surgeon Dr. Adam Rubinstein to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Adam Rubinstein, board-certified plastic surgeon in Miami, joined Carmell's Scientific Advisory Board on Jan 9, 2024.","He serves as voluntary clinical associate professor at University of Miami, NOVA Southeastern, and FIU College of Medicine.","Named one of America's top plastic surgeons every year since 2007 and featured in Newsweek top surgeons list.","Chairman & CEO Rajiv Shukla cites Rubinstein's expertise in latest plastic surgery techniques as excellent fit.","Rubinstein praised Carmell's secretome technology as a tremendous advancement for aesthetic treatment outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249563,"accession_number":"0000950170-24-004758","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Carmell adds double board-certified surgeon Dr. Jason Bloom to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Bloom is a facial plastic and reconstructive surgeon, trained at University of Pennsylvania and NYU.","He owns Bloom Facial Plastic Surgery in Bryn Mawr, PA and holds academic appointments at Penn and Temple.","Dr. Bloom has authored over 50 journal articles and serves as co-director of a facial surgery fellowship.","CEO Rajiv Shukla cited Bloom's leadership in aesthetics and scientific innovation in the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249561,"accession_number":"0000950170-24-004782","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carmell adds Dr. Adam Rubinstein, board-certified plastic surgeon, to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Dr. Rubinstein is a board-certified plastic surgeon in Miami, FL, and clinical faculty at multiple universities.","He has been named one of America's top plastic surgeons every year since 2007 and featured in Newsweek's top 30.","Chairman & CEO Rajiv Shukla cited Dr. Rubinstein's expertise in latest cosmetic surgery techniques for the appointment.","Dr. Rubinstein praised Carmell's secretome technology as a 'tremendous advancement' in aesthetic treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249560,"accession_number":"0000950170-24-004775","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Carmell adds Dr. Jason Bloom to Scientific Advisory Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Bloom is a double board-certified facial plastic surgeon, Ivy-League trained.","He serves as Adjunct Assistant Professor at UPenn and Temple, and Co-Director of a fellowship.","CEO Rajiv Shukla highlights Bloom's leadership in aesthetics and scientific innovation.","Bloom will collaborate on regenerative aesthetics products emphasizing science, safety, results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249562,"accession_number":"0000950170-24-002495","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Carmell enters CEO employment agreement with Rajiv Shukla; $425K total comp, severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Rajiv Shukla receives total annual compensation of $425,000: 75% cash ($318,750 base), 25% in quarterly vested shares.","Annual bonus target is 50% of total comp ($212,500), paid 75% cash, 25% stock, based on board discretion.","Severance on termination without cause: 12 months base salary outside protected period; 18 months salary plus target bonus and equity acceleration during protected period.","Agreement effective July 15, 2023; includes restrictive covenants on confidentiality, non-compete, non-solicit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267027,"accession_number":"0001193125-23-278158","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Carmell appoints Scott Frisch (AARP COO/CFO) and Gilles Spenlehauer as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Frisch, COO/CFO of AARP, joins audit committee.","Gilles Spenlehauer, Scientific Director at SDTech, ex-L'Oreal research head, joins nominating committee.","Both directors are independent under Nasdaq rules and serve as Class II until 2024 annual meeting.","Compensation committee unchanged; no arrangements or transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267026,"accession_number":"0001193125-23-262976","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2023-10-25T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Carmell Corp files Axolotl Biologix H1 2023 financials: rev $21.9M, NI $1.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Axolotl H1 2023 revenue $21.9M (up 56% YoY from $14.0M) and net income $1.8M (up 57% from $1.2M).","Single customer (Customer A) and single product (Dualgraft) represent 100% of revenue.","Cash and equivalents $698k; accounts receivable $17.2M; inventory $2.6M.","Related-party loans from Burns Ventures $5.6M noncurrent; inventory purchases from Pinnacle $2.5M in H1 2023.","Operating cash flow negative $701k; cash decreased from $1.4M to $698k in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284305,"accession_number":"0001193125-23-229630","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Carmell announces CEO change, board restructuring, and post-merger savings focus on aesthetics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Randy Hubbell resigns effective Aug 31, 2023; Rajiv Shukla (Exec Chair) appointed Chairman & CEO.","Four directors and four other execs depart as part of Axolotl Biologix integration; no disagreement cited.","$8M milestone payment to Axolotl rescheduled to Aug 31, 2024; projected annual savings of ~$3M from terminations.","Focus narrowed to aesthetics programs (skin rejuvenation, dental bone healing) with shorter path to commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284302,"accession_number":"0001193125-23-212571","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2023-08-15T23:59:59+00:00","items":["9.01","2.01","5.02"],"status":"ready","headline":"Carmell Corp files amended 8-K with historical unaudited financials of Legacy Carmell for H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $7.1M for six months ended June 30, 2023; accumulated deficit reached $50.1M.","Cash balance only $15,920 at June 30, 2023, with $14.7M current liabilities and $4.7M derivative liabilities.","Business Combination closed July 14, 2023; shares commenced trading on Nasdaq July 17, 2023 under ticker CTCX.","Pro forma unaudited condensed combined financials for FY 2022 and H1 2023 filed as Exhibit 99.3.","Bryan Cassaday appointed Interim CFO; executive leadership includes Exec Chairman Rajiv Shukla and CEO Randolph Hubbell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284304,"accession_number":"0001193125-23-211437","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Carmell completes acquisition of Axolotl Biologix; $8M cash + $57M stock at closing, up to $75M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed merger with Axolotl on Aug 9, 2023; issued 3,845,337 common shares and 4,243 Series A preferred shares.","Initial consideration: $8M cash (contingent on audited financials) and $57M in equity valued at $7.05/share VWAP.","Up to $75M in milestone payments tied to revenue targets, contract execution, and clinical milestones.","Company rebranded as Carmell Corporation targeting $100M FY24 revenue and a cosmeceutical launch by FY24."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284303,"accession_number":"0001193125-23-200597","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Carmell Corp to acquire Axolotl Biologix for up to $140M; Axolotl TTM rev $50M, EBITDA $5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Axolotl had unaudited TTM revenue ~$50M and TTM EBITDA ~$5M as of June 30, 2023.","Initial consideration: $8M cash + $57M in CTCX stock ($65M total), plus up to $75M in milestone payments.","Axolotl's human amnion allografts are FDA-compliant; two products added to CMS Part B pricing in Q2 2023.","Transaction expected to close in Q3 2023; Axolotl shareholders subject to 12-month lock-up.","Company changes name to Carmell Corporation; Axolotl CEO Josh Sandberg becomes Strategic Advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284301,"accession_number":"0001193125-23-190559","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["1.01","2.01","5.06","9.01","5.02","3.02","4.01","3.03","5.01","5.03","5.05","7.01"],"status":"ready","headline":"Carmell Therapeutics completes de-SPAC merger; $129.4M redeemed, 19.2M shares outstanding","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed July 14, 2023; ALPA renamed to Carmell Therapeutics (CTCX).","12.6M shares redeemed at $10.00 each, depleting ~$129.4M from trust.","Post-merger shares outstanding: 19,236,305; top holder AHAC Sponsor III LLC holds 19.68%.","Rajiv Shukla appointed Executive Chairman; one-year lock-up for certain stockholders, sponsor faces 5-year lock-up on 50% of founder shares.","Indemnification agreements and 2023 Long-Term Incentive Plan adopted; warrants trade under CTCXW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284300,"accession_number":"0001193125-23-187042","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alpha Healthcare III to close Carmell merger on July 14; 12.6M shares redeemed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the business combination on July 11, 2023; 12,586,223 Class A shares were redeemed.","Preliminary pro forma stockholders' equity estimated at approximately $16.1 million as of March 31, 2023.","The Business Combination closes July 14; New Carmell shares expected to trade on Nasdaq starting July 17.","A full set of pro forma financials will be filed on Form 8-K within four business days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284299,"accession_number":"0001193125-23-185922","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alpha Healthcare shareholders approve merger with Carmell Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Business combination proposal approved: 12,006,101 for, 3,504,978 against.","All seven charter amendments approved, including name change to Carmell Therapeutics Corp.","Issuance of up to 15M shares of New Carmell common stock approved.","Nine directors elected for combined company, including Rich Upton and William Newlin.","Adjournment proposal passed with 13,169,774 votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284298,"accession_number":"0001193125-23-184219","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alpha Healthcare enters forward purchase and non-redemption agreements to support Carmell merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sellers (Meteora entities) may purchase up to 9.5% of outstanding shares at redemption price; prepayment from trust account.","Non-redemption agreement covers 100,000 shares; sellers waive redemption rights on recycled shares purchased before close.","Prepayment amount = Number of Shares × Initial Price; settlement via physical delivery on first anniversary or earlier trigger.","Optional early termination: seller can unwind if VWAP ≥ Reset Price ($11.50 floor); buyer pays Early Termination Obligation.","Combined company must file resale registration within 45-60 days of seller request; failure triggers Registration Failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284297,"accession_number":"0001193125-23-182843","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alpha Healthcare provides Carmell merger update; LOI for commercial stage allograft company with $50M revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholder vote for Carmell merger scheduled July 11, 2023; redemption deadline July 7.","Non-binding LOI to acquire a commercial stage allograft company with ~$50M TTM revenue and ~$5M EBITDA.","Deal terms: $65M initial equity ($8M cash + $57M stock) plus up to $75M milestone payments (12% cash, 88% stock); 12-month lockup.","Carmell's pipeline: Phase 2 tibia fracture trial (Fast Track), FDA agreed HEAL II start; foot/ankle fusion program.","Post-merger ticker CTCX; plan to build leading player in aesthetics and orthopedics through roll-ups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-07-06T23:59:59+00:00|284297"}